Alumis reports 48-week psoriasis symptom data
Alumis has reported 48-week psoriasis symptom data from its TYK2 inhibitor program, extending durability evidence well past the standard 16-week trial window.
Topic
Clinical Trial Data
Topic
Topic
Topic
Alumis has reported 48-week psoriasis symptom data from its TYK2 inhibitor program, extending durability evidence well past the standard 16-week trial window.